IL139592A - Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression - Google Patents

Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression

Info

Publication number
IL139592A
IL139592A IL13959299A IL13959299A IL139592A IL 139592 A IL139592 A IL 139592A IL 13959299 A IL13959299 A IL 13959299A IL 13959299 A IL13959299 A IL 13959299A IL 139592 A IL139592 A IL 139592A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
composition containing
combination therapy
serotonin reuptake
reuptake inhibitor
Prior art date
Application number
IL13959299A
Other languages
English (en)
Other versions
IL139592A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL139592A0 publication Critical patent/IL139592A0/xx
Publication of IL139592A publication Critical patent/IL139592A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
IL13959299A 1998-05-22 1999-05-21 Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression IL139592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22
PCT/US1999/011276 WO1999061027A1 (en) 1998-05-22 1999-05-21 Combination therapy for treatment of refractory depression

Publications (2)

Publication Number Publication Date
IL139592A0 IL139592A0 (en) 2002-02-10
IL139592A true IL139592A (en) 2005-08-31

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13959299A IL139592A (en) 1998-05-22 1999-05-21 Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression

Country Status (24)

Country Link
EP (1) EP0958824A3 (enExample)
JP (1) JP2002516282A (enExample)
KR (1) KR20010043730A (enExample)
CN (1) CN1154496C (enExample)
AU (1) AU761510B2 (enExample)
BR (1) BR9911049A (enExample)
CA (1) CA2332814C (enExample)
CZ (1) CZ20004279A3 (enExample)
EA (1) EA004539B1 (enExample)
HK (1) HK1040055B (enExample)
HR (1) HRP20000797A2 (enExample)
HU (1) HUP0101901A3 (enExample)
ID (1) ID26861A (enExample)
IL (1) IL139592A (enExample)
MY (1) MY127938A (enExample)
NO (1) NO20005885L (enExample)
NZ (1) NZ507980A (enExample)
PL (1) PL344331A1 (enExample)
SK (1) SK17512000A3 (enExample)
TR (1) TR200003443T2 (enExample)
TW (1) TWI226829B (enExample)
UA (1) UA78181C2 (enExample)
WO (1) WO1999061027A1 (enExample)
ZA (1) ZA200006815B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2003295235B2 (en) 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005056056A2 (en) * 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
HRP20141008T1 (hr) * 2007-02-09 2015-01-02 Alphapharm Pty Ltd Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP2000506859A (ja) * 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 双極性障害の処置方法
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
CN1311681A (zh) 2001-09-05
EP0958824A3 (en) 1999-12-01
KR20010043730A (ko) 2001-05-25
AU4008699A (en) 1999-12-13
HUP0101901A3 (en) 2002-06-28
BR9911049A (pt) 2001-02-06
AU761510B2 (en) 2003-06-05
JP2002516282A (ja) 2002-06-04
EA004539B1 (ru) 2004-06-24
HK1040055B (zh) 2005-04-01
WO1999061027A1 (en) 1999-12-02
ZA200006815B (en) 2002-01-14
EA200001218A1 (ru) 2001-06-25
TWI226829B (en) 2005-01-21
CZ20004279A3 (cs) 2001-09-12
UA78181C2 (en) 2007-03-15
ID26861A (id) 2001-02-15
NO20005885D0 (no) 2000-11-21
HUP0101901A2 (hu) 2001-11-28
NO20005885L (no) 2001-01-17
IL139592A0 (en) 2002-02-10
EP0958824A2 (en) 1999-11-24
NZ507980A (en) 2003-10-31
MY127938A (en) 2007-01-31
HK1040055A1 (en) 2002-05-24
HRP20000797A2 (en) 2001-10-31
CN1154496C (zh) 2004-06-23
SK17512000A3 (sk) 2002-02-05
PL344331A1 (en) 2001-11-05
TR200003443T2 (tr) 2001-03-21
CA2332814C (en) 2008-11-04
CA2332814A1 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
IL139592A (en) Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression
ZA987800B (en) Pharmaceutical composition of meloxicam
HUP0002183A3 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
CA2264941A1 (en) Use of a combination of an atypical antipsychotic and a serotonin reuptake inhibitor for treatment of psychosis
IL121076A0 (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL115315A0 (en) Synthesis of 3-(4-(2-aminoethoxy)-benzoyl)-2-aryl-6-hydroxybenzo (b) thiophenes
IL136086A0 (en) New composition of matter
IL133605A0 (en) Solid pharmaceutical composition containing benzofuran derivatives
IL138129A (en) Composition for therapy of estrogen-associated disorders
HUP0300534A3 (en) Antitumoral ecteinascidin derivatives and pharmaceutical compositions containing them
HUP0200602A3 (en) Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
PT1067941E (pt) Composicao antitumoral contendo uma combinacao sinergica de um derivado de antraciclina com um derivado de camptotecina
PT1121116E (pt) Composição farmacêutica de libertação sustentada de fluvastatina
HUP0301830A3 (en) Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
IL159040A0 (en) A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
HUP0103071A3 (en) Pharmaceutical composition containing citalopram
PL340456A1 (en) Novel oral dosage form of carvedilol
AU140181S (en) Bottle of perfume
HUP0101224A3 (en) Pyrrolidine derivatives as inhibitors of neuraminidases and pharmaceutical compositions containing them
HU0103939D0 (en) Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
AU1193199A (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists
IL144027A0 (en) A pharmaceutical composition containing a pre-activation domain and at least one kringle region from plasminogen
EP0996441A4 (en) PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES
HUP0303497A3 (en) Pharmaceutical compositions containing combination of statins and sorbitol dehydrogenase inhibitors

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees